Value viewpoint – recent developments in US healthcare value and access with Kimberly Westrich: November–December 2023

In this bi-monthly column, Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) discusses the recent updates in US healthcare value and access from November and December 2023. What happened over these months that you were expecting? As the Centers for Medicare and Medicaid Services (CMS) began the process of implementing drug price negotiation under the Inflation Reduction Act (IRA), there was continued speculation about the process and its potential impact on the ecosystem. An article by Sean Sullivan, Inmaculada Hernandez, Scott Ramsey, and Peter Neumann in Value in Health considered whether CMS had implicitly created a value assessment framework for...